전립선비대증 환자에서 항콜린제 추가 투여 시 순응도에 영향을 미치는 요인
The Factors Affecting the Compliance of Additional Anticholinergic Medication in the Patients with Benign Prostatic Hyperplasia
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Anticholinergic agents are effective in relieving overactive bladder symptoms and historically has been contraindicated in benign prostatic hyperplaisa (BPH) patients because of concerns for developing acute urinary retention. Recently, however, treatment for men with predominant storage symptoms is combined with an antichoilnergic agents. We evaluated the efficacy, discontinuation rate, adverse events and clinical parameters of α-blockers and/or 5α-reductase inhibitors treatment combined with anticholinergic agents in patients with lower urinary tract symptoms (LUTS). Materials and Methods: 137 patients with BPH, who had treated with α-blockers and/or 5α-reductase inhibitors combined with anticholinergic agents at our department from January 2003 to November 2008, were retrospectively studied. In 92 patients, anticholinergic agents continued to be administered (group I) and in 45 patients, ceased to be given (group II). The efficacy and adverse events of anticholinergics treatment were estimated. The International Prostate Symptom Score (IPSS), serum prostate specific antigen (PSA) level, prostate volume, maximum urinary flow rate and residual urine volume before administration of anticholinergics were evaluated. The change in maximum urinary flow rate and residual urine volume and the presence of acute urinary retention after giving anticholinergics were compared. Results: There was no significant difference comparing age, IPSS, serum PSA levels, prostate volum, maximum urinary flow rate and residual urine volume except IPSS storage subscore between the two groups. In group I, there was no significant change in maximum urinary flow rate and residual urine volume after administering anticholinergics. IPSS storage subscore were more significant in group I (9.0±3.4 vs 7.4±3.4, p<0.05). The duration of anticholinergics administration was longer in group I than II (325.0±316.7 vs 95.5±96.1). The discontinuation rate was 32.8%. Nocturia (n=48), frequency (n=28) and urgency (n=16) were significantly improved in group I after additional anticholinergic medication. Adverse events causing discontinuation in group II were the increase of residual sensation (n=13), difficult voiding (n=12), dry mouth (n=6), hesitancy (n=6) and constipation (n=2). Acute urinary retention was not reported in both groups. Conclusions: In men with LUTS suggestive of BPH, anticholinergic treatment appears to be safe and when the storage symptoms were severer, the better compliance was. The overall discontinuation rate was 32.8%, and acute urinary retention was not reported. (J Korean Continence Soc 2009;13:45-50)
Abstract
Purpose: Anticholinergic agents are effective in relieving overactive bladder symptoms and historically has been contraindicated in benign prostatic hyperplaisa (BPH) patients because of concerns for developing acute urinary retention. Recently, however, treatment for men with predominant storage symptoms is combined with an antichoilnergic agents. We evaluated the efficacy, discontinuation rate, adverse events and clinical parameters of α-blockers and/or 5α-reductase inhibitors treatment combined with anticholinergic agents in patients with lower urinary tract symptoms (LUTS). Materials and Methods: 137 patients with BPH, who had treated with α-blockers and/or 5α-reductase inhibitors combined with anticholinergic agents at our department from January 2003 to November 2008, were retrospectively studied. In 92 patients, anticholinergic agents continued to be administered (group I) and in 45 patients, ceased to be given (group II). The efficacy and adverse events of anticholinergics treatment were estimated. The International Prostate Symptom Score (IPSS), serum prostate specific antigen (PSA) level, prostate volume, maximum urinary flow rate and residual urine volume before administration of anticholinergics were evaluated. The change in maximum urinary flow rate and residual urine volume and the presence of acute urinary retention after giving anticholinergics were compared. Results: There was no significant difference comparing age, IPSS, serum PSA levels, prostate volum, maximum urinary flow rate and residual urine volume except IPSS storage subscore between the two groups. In group I, there was no significant change in maximum urinary flow rate and residual urine volume after administering anticholinergics. IPSS storage subscore were more significant in group I (9.0±3.4 vs 7.4±3.4, p<0.05). The duration of anticholinergics administration was longer in group I than II (325.0±316.7 vs 95.5±96.1). The discontinuation rate was 32.8%. Nocturia (n=48), frequency (n=28) and urgency (n=16) were significantly improved in group I after additional anticholinergic medication. Adverse events causing discontinuation in group II were the increase of residual sensation (n=13), difficult voiding (n=12), dry mouth (n=6), hesitancy (n=6) and constipation (n=2). Acute urinary retention was not reported in both groups. Conclusions: In men with LUTS suggestive of BPH, anticholinergic treatment appears to be safe and when the storage symptoms were severer, the better compliance was. The overall discontinuation rate was 32.8%, and acute urinary retention was not reported. (J Korean Continence Soc 2009;13:45-50)
참고문헌 (17)
- Rosier PF, "Is detrusor instanility in elderly males related to the grade of obstruction?", Neurourol Urodyn, 14, pp.625~633 (1995)
- Rosenberg MT, "A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting", Int J Clin Pract, 61, pp.1535~1546 (2007)
- Chapple CR, "The pathophysiological changes in the bladder obstructed by benign prostatic hyper- plasia", Br J Urol, 73, pp.117~123 (1994)
- Abrams PH, "The results of prostatectomy: a symptomatic and urodynamic analysis of 152 patients", Urol, 121, pp.640~642 (1979)
- AUA Practice Guidelines Committee, "AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations", J Urol, 170, pp.530~47 (2003)
- Peters TJ, "The International Continence Society "Benign Prostatic Hyperplasia" Study: the bothersomeness of urinary symptoms", J Urol, 157, pp.885~889 (1997)
- Abrams P, "Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction", J Urol, 175, pp.999~1004 (2006)
- Chapple CR, "A three month double-blind study of doxazsin as treatment for benign prostatic bladder outlet obstruction", Br J Urol, 74, pp.50~56 (1994)
- Thomas AW, "Lower urinary tract symptoms, benign prostatic obstruction and the overactive bladder", BJU Int, 85, pp.57~68 (2000)
- Greenland JE, "The effect of bladder outflow obstruction on detrusor blood flow changes during the voiding cycle in conscious pigs", 165, pp.245~248 (2001)
- Saito H, "A comparative study of the efficacy and safety of tamsulosin hydrochloride alone and combination of propiverine hydrochloride and tamsulosin hydrochloride in the benign prostatic hypertrophy with pollakisuria and", or urinary incontinence, 1999, pp.12, 525~536
- Lee JY, "Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder", BJU Int, 94, pp.817~820 (2004)
- Lee KS, "Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study", J Urol, 174, pp.1334~1338 (2005)
- Athanasopoulos A, "Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study", J Urol, 169, pp.2253~2256 (2003)
- 이건철, "과민성방광을 동반한 하부요로증상 환자에서알파차단제와 항콜린제 병용투여의 효과", International Neurourology Journal, 11(1), pp.63~67 (2007), 대한배뇨장애요실금학회
- Blake-James BT, "The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis", BJU Int, 99, pp.85~96 (2007)
- Andersson KE, "Antinuscarinics and the overactive detrusor-which is the main mechanism of action?", Eur Urol, 43, pp.1~5 (2003)